全文获取类型
收费全文 | 172388篇 |
免费 | 33961篇 |
国内免费 | 2524篇 |
专业分类
耳鼻咽喉 | 5342篇 |
儿科学 | 5886篇 |
妇产科学 | 2813篇 |
基础医学 | 6509篇 |
口腔科学 | 1709篇 |
临床医学 | 28696篇 |
内科学 | 52539篇 |
皮肤病学 | 7691篇 |
神经病学 | 16989篇 |
特种医学 | 7121篇 |
外国民族医学 | 1篇 |
外科学 | 45186篇 |
综合类 | 387篇 |
现状与发展 | 72篇 |
一般理论 | 9篇 |
预防医学 | 8425篇 |
眼科学 | 3593篇 |
药学 | 2377篇 |
中国医学 | 83篇 |
肿瘤学 | 13445篇 |
出版年
2024年 | 521篇 |
2023年 | 4870篇 |
2022年 | 1338篇 |
2021年 | 3500篇 |
2020年 | 6319篇 |
2019年 | 2693篇 |
2018年 | 7930篇 |
2017年 | 7728篇 |
2016年 | 8852篇 |
2015年 | 8934篇 |
2014年 | 16229篇 |
2013年 | 16656篇 |
2012年 | 7108篇 |
2011年 | 7256篇 |
2010年 | 11391篇 |
2009年 | 15191篇 |
2008年 | 7339篇 |
2007年 | 5631篇 |
2006年 | 7974篇 |
2005年 | 5356篇 |
2004年 | 4432篇 |
2003年 | 3430篇 |
2002年 | 3552篇 |
2001年 | 3983篇 |
2000年 | 3163篇 |
1999年 | 3435篇 |
1998年 | 3940篇 |
1997年 | 3743篇 |
1996年 | 3551篇 |
1995年 | 3402篇 |
1994年 | 2096篇 |
1993年 | 1711篇 |
1992年 | 1492篇 |
1991年 | 1509篇 |
1990年 | 1156篇 |
1989年 | 1255篇 |
1988年 | 1094篇 |
1987年 | 911篇 |
1986年 | 979篇 |
1985年 | 794篇 |
1984年 | 631篇 |
1983年 | 604篇 |
1982年 | 610篇 |
1981年 | 485篇 |
1980年 | 446篇 |
1979年 | 360篇 |
1978年 | 373篇 |
1977年 | 432篇 |
1975年 | 311篇 |
1972年 | 325篇 |
排序方式: 共有10000条查询结果,搜索用时 687 毫秒
11.
12.
13.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
14.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
15.
16.
17.
18.
Evelyne Harkemanne Jean‐Louis Dargent Pierre‐Paul Roquet‐Gravy Audrey Bulinckx 《Pediatric dermatology》2019,36(3):365-367
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm. 相似文献
19.
20.
Ingmar Fleps Pierre Guy Stephen J Ferguson Peter A Cripton Benedikt Helgason 《Journal of bone and mineral research》2019,34(10):1837-1850
The majority of hip fractures in the elderly are the result of a fall from standing or from a lower height. Current injury models focus mostly on femur strength while neglecting subject-specific loading. This article presents an injury modeling strategy for hip fractures related to sideways falls that takes subject-specific impact loading into account. Finite element models (FEMs) of the human body were used to predict the experienced load and the femoral strength in a single model. We validated these models for their predicted peak force, effective pelvic stiffness, and fracture status against matching ex vivo sideways fall impacts (n = 11) with a trochanter velocity of 3.1 m/s. Furthermore, they were compared to sideways impacts of volunteers with lower impact velocities that were previously conducted by other groups. Good agreement was found between the ex vivo experiments and the FEMs with respect to peak force (root mean square error [RMSE] = 10.7%, R2 = 0.85) and effective pelvic stiffness (R2 = 0.92, RMSE = 12.9%). The FEMs were predictive of the fracture status for 10 out of 11 specimens. Compared to the volunteer experiments from low height, the FEMs overestimated the peak force by 25% for low BMI subjects and 8% for high BMI subjects. The effective pelvic stiffness values that were derived from the FEMs were comparable to those derived from impacts with volunteers. The force attenuation from the impact surface to the femur ranged between 27% and 54% and was highly dependent on soft tissue thickness (R2 = 0.86). The energy balance in the FEMS showed that at the time of peak force 79% to 93% of the total energy is either kinetic or was transformed to soft tissue deformation. The presented FEMs allow for direct discrimination between fracture and nonfracture outcome for sideways falls and bridge the gap between impact testing with volunteers and impact conditions representative of real life falls. © 2019 American Society for Bone and Mineral Research. 相似文献